Comparison of the Effectiveness of Moderate-Intensity Interval Training With and without spirulina supplementation in Control of monocyte chemoattractant inflammatory proteins-1

Comparison of the Effectiveness of eight weeks of Moderate-Intensity Interval Training With and without spirulina supplementation in Control of Monocyte Chemoattractant Inflammatory Protein-1, Interleukin-10, and lipid profile of overweight women

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120129008863N11

Enrollment

Registered

2025-07-05

Start date

2025-07-07

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and obesity. Overweight and obesity

Interventions

Intervention 1: In this group, participants will take two 500 mg spirulina capsules daily (morning and evening) for eight weeks. Reyhaneh Isfahan Pharmaceutical Company is providing the spirulina supp

Eligibility

Sex/Gender

Female

Age

30 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inactive Female, aged 30 to 35 In good general physical and mental health Body mass index greater than 25 kg/m²

Exclusion criteria

Exclusion criteria: Any physical injury or orthopedic issue that interferes with training can hinder its quality.

Design outcomes

Primary

Measure	Time frame
Monocyte chemoattractant inflammatory proteins-1. Timepoint: Before the intervention and two months following it. Method of measurement: zellBio kit (mmol/l).;Interleukin-10. Timepoint: Before the intervention and two months following it. Method of measurement: zellBio kit (mmol/l).;Triglyceride. Timepoint: Before the intervention and two months following it. Method of measurement: ParsAzmon Kit (mg/dl).;Total Cholesterol. Timepoint: Before the intervention and two months following it. Method of measurement: ParsAzmon Kit (mg/dl).;Low lipoprotein. Timepoint: Before the intervention and two months following it. Method of measurement: ParsAzmon Kit (mg/dl).;High-lipoprotein. Timepoint: Before the intervention and two months following it. Method of measurement: ParsAzmon Kit (mg/dl).	—

Measure

Time frame

Monocyte chemoattractant inflammatory proteins-1. Timepoint: Before the intervention and two months following it. Method of measurement: zellBio kit (mmol/l).;Interleukin-10. Timepoint: Before the intervention and two months following it. Method of measurement: zellBio kit (mmol/l).;Triglyceride. Timepoint: Before the intervention and two months following it. Method of measurement: ParsAzmon Kit (mg/dl).;Total Cholesterol. Timepoint: Before the intervention and two months following it. Method of measurement: ParsAzmon Kit (mg/dl).;Low lipoprotein. Timepoint: Before the intervention and two months following it. Method of measurement: ParsAzmon Kit (mg/dl).;High-lipoprotein. Timepoint: Before the intervention and two months following it. Method of measurement: ParsAzmon Kit (mg/dl).

—

Secondary

Measure	Time frame
Body Mass Index (BMI) Kg/m2. Timepoint: Before the intervention and two months following it. Method of measurement: The body mass (kg) divided by the square of the body height (cm).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Keyvan Hejazi

Hakim Sabzevari University

k.hejazi@hsu.ac.ir+98 51 4401 2767

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026